Vor Bio Announces $175 Million Private Placement
Vor Bio (Nasdaq: VOR) has secured a $175 million private placement through the issuance of prefunded warrants. The company will issue 700,000,000 warrants at $0.25 per warrant with an exercise price of $0.0001 per share.
The PIPE financing includes notable investors such as RA Capital Management, Mingxin Capital, Forbion, Venrock Healthcare Capital Partners, Caligan Partners, and NEXTBio. The proceeds will support the development of Vor Bio's clinical pipeline and general corporate purposes. The placement is expected to close on June 27, 2025, subject to stockholder approval and customary conditions.
Vor Bio (Nasdaq: VOR) ha ottenuto un finanziamento privato di 175 milioni di dollari attraverso l'emissione di warrant prefunded. La società emetterà 700.000.000 warrant al prezzo di 0,25 dollari per warrant con un prezzo di esercizio di 0,0001 dollari per azione.
Il finanziamento PIPE include investitori di rilievo come RA Capital Management, Mingxin Capital, Forbion, Venrock Healthcare Capital Partners, Caligan Partners e NEXTBio. I proventi supporteranno lo sviluppo del pipeline clinico di Vor Bio e le esigenze generali aziendali. La chiusura dell'operazione è prevista per il 27 giugno 2025, subordinata all'approvazione degli azionisti e alle condizioni consuete.
Vor Bio (Nasdaq: VOR) ha asegurado una colocación privada de 175 millones de dólares mediante la emisión de warrants prefinanciados. La empresa emitirá 700.000.000 warrants a 0,25 dólares por warrant con un precio de ejercicio de 0,0001 dólares por acción.
La financiación PIPE incluye inversores destacados como RA Capital Management, Mingxin Capital, Forbion, Venrock Healthcare Capital Partners, Caligan Partners y NEXTBio. Los fondos se destinarán al desarrollo de la cartera clínica de Vor Bio y a propósitos corporativos generales. Se espera que la colocación cierre el 27 de junio de 2025, sujeta a la aprobación de los accionistas y condiciones habituales.
Vor Bio (나스닥: VOR)는 선납 워런트 발행을 통해 1억 7,500만 달러의 사모 투자를 확보했습니다. 회사는 7억 개의 워런트를 워런트당 0.25달러에 발행하며, 행사 가격은 주당 0.0001달러입니다.
이번 PIPE 자금 조달에는 RA Capital Management, Mingxin Capital, Forbion, Venrock Healthcare Capital Partners, Caligan Partners, NEXTBio 등 주요 투자자들이 참여했습니다. 조달된 자금은 Vor Bio의 임상 파이프라인 개발과 일반 기업 목적에 사용될 예정입니다. 주주 승인 및 통상적인 조건 충족을 전제로 2025년 6월 27일에 거래가 마무리될 예정입니다.
Vor Bio (Nasdaq : VOR) a sécurisé un placement privé de 175 millions de dollars via l'émission de bons de souscription préfinancés. La société émettra 700 000 000 bons de souscription au prix de 0,25 dollar par bon avec un prix d'exercice de 0,0001 dollar par action.
Le financement PIPE inclut des investisseurs notables tels que RA Capital Management, Mingxin Capital, Forbion, Venrock Healthcare Capital Partners, Caligan Partners et NEXTBio. Les fonds serviront à soutenir le développement du pipeline clinique de Vor Bio ainsi qu'à des fins générales d'entreprise. La clôture du placement est prévue pour le 27 juin 2025, sous réserve de l'approbation des actionnaires et des conditions habituelles.
Vor Bio (Nasdaq: VOR) hat eine Privatplatzierung über 175 Millionen US-Dollar durch die Ausgabe von vorfinanzierten Warrants gesichert. Das Unternehmen wird 700.000.000 Warrants zu je 0,25 US-Dollar pro Warrant mit einem Ausübungspreis von 0,0001 US-Dollar pro Aktie ausgeben.
Zu den bedeutenden Investoren der PIPE-Finanzierung zählen RA Capital Management, Mingxin Capital, Forbion, Venrock Healthcare Capital Partners, Caligan Partners und NEXTBio. Die Erlöse werden die Entwicklung der klinischen Pipeline von Vor Bio sowie allgemeine Unternehmenszwecke unterstützen. Der Abschluss der Platzierung wird für den 27. Juni 2025 erwartet, vorbehaltlich der Zustimmung der Aktionäre und üblicher Bedingungen.
- Secured substantial financing of $175 million from world-class investors
- Support from existing stockholder RA Capital Management demonstrates confidence
- Proceeds will advance clinical pipeline development
- Significant potential dilution with 700,000,000 new shares
- Requires stockholder approval for warrant exercise
- Shares will be unregistered and subject to Securities Act restrictions
Insights
Vor Bio secures critical $175M funding at significant discount, providing runway but heavily diluting existing shareholders.
Vor Bio has secured a crucial
This financing structure suggests the company faced significant challenges raising capital through traditional means. While the capital infusion provides essential runway to advance their clinical pipeline for autoimmune diseases, the massive share count increase will dramatically dilute current shareholders. With 700 million new shares potentially entering circulation, existing investors will own a substantially smaller percentage of the company post-transaction.
The participation of existing investor RA Capital alongside new investors including Mingxin Capital and Forbion does provide some validation. However, the warrant structure at such a deep discount indicates these sophisticated investors negotiated extremely favorable terms, suggesting concerns about Vor's valuation or cash position.
The deal requires shareholder approval, and management will likely face difficult questions about why such dilutive financing was necessary. While the funding provides vital operational runway, the terms signal serious challenges that investors should scrutinize carefully.
CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it has entered into a securities purchase agreement for a private placement in public equity financing (the “PIPE”) that is expected to result in gross proceeds of approximately
Private Placement
Pursuant to the terms of the securities purchase agreement, at the closing of the PIPE, Vor Bio will issue prefunded warrants (the “Warrants”) to purchase an aggregate of 700,000,000 shares of common stock at a purchase price of
The PIPE included a syndicate of world-class investors including Vor Bio’s existing stockholder RA Capital Management, as well as Mingxin Capital, Forbion, Venrock Healthcare Capital Partners, Caligan Partners and NEXTBio.
Vor Bio intends to use the net proceeds from the PIPE to advance development of its clinical pipeline and for general corporate purposes. The PIPE is expected to close on June 27, 2025, subject to the satisfaction of customary closing conditions.
The Warrants have an exercise price of
The securities being issued and sold in the PIPE have not been registered under the Securities Act of 1933, as amended (the “Securities Act”). Accordingly, these securities may not be offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. Concurrently with the execution of the securities purchase agreement, Vor Bio and the investors named therein entered into a registration rights agreement pursuant to which Vor Bio has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock issuable upon the exercise of the Warrants.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “aim,” “anticipate,” “can,” “continue,” “could,” “design,” “enable,” “expect,” “initiate,” “intend,” “may,” “on-track,” “ongoing,” “plan,” “potential,” “should,” “target,” “update,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include Vor Bio’s statements regarding the PIPE, including expected proceeds, expected use of proceeds and expected closing, expectations and timing with respect to a special stockholder meeting and other statements that are not historical fact. Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors. These and other risks are described in greater detail under the caption “Risk Factors” included in Vor Bio’s most recent annual or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Vor Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.
Contact:
Investors & Media
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com
FAQ
What is the size and price of Vor Bio's (VOR) private placement announced on June 25, 2025?
Who are the investors participating in Vor Bio's (VOR) PIPE financing?
How many warrants will Vor Bio (VOR) issue in the private placement?
What will Vor Bio (VOR) use the private placement proceeds for?
When will Vor Bio's (VOR) private placement close?
